GlassScriptPhysician profile
Jeffrey R Jamison
NPI 1811068836
$5,411.06
in general payments reported to CMS, 2019-2025
49 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $877 · 2021: $1,030 · 2022: $923 · 2023: $844 · 2024: $671 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $758.71 | 2021-2025 | |
| Amgen INC. | $657.40 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $422.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $333.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.36 | 2020-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $288.78 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Janssen Pharmaceuticals, INC | $264.75 | 2019-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $220.65 | 2019-2025 | Austedo Xr, Austedo Xr |
| Allergan, INC. | $168.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $143.10 | 2019-2024 | Airsupra |
| Astellas Pharma US INC | $142.17 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.48 | 2019-2023 | Trulance, Xifaxan |
| Medtronic, INC. | $114.37 | 2022-2025 | Minimed 780g, Kyphon Express II Kyphopak Tray |
| Takeda Pharmaceuticals U.S.A., INC. | $112.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $106.43 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jamison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.